Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Dec;151(5):430-4.
doi: 10.1111/j.1365-2141.2010.08387.x.

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

Anjali S Advani  1 , Holly M Gundacker, Olga Sala-Torra, Jerald P Radich, Raymond Lai, Marilyn L Slovak, Jeffrey E Lancet, Steve E Coutre, Robert K Stuart, Martha P Mims, Patrick J Stiff, Frederick R Appelbaum
Affiliations
Clinical Trial

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

Anjali S Advani et al. Br J Haematol. 2010 Dec.

Abstract

Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo, and have non-overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia. Thirty-seven patients were treated. The median age was 41 years, 44% of patients were either in ≥2nd relapse or had refractory disease and 59% of patients had poor risk cytogenetics. Six out of 36 patients (17%) achieved a complete remission with or without complete count recovery; median overall survival was 3 months. Nucleoside transporter expression did not predict outcome. This regimen lacked sufficient activity to warrant further testing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative immunohistochemistry demonstrating a patient with low (0) hENT1 expression (A) and high (2+) hENT1 expression (magnification × 400).
Figure 1
Figure 1
Representative immunohistochemistry demonstrating a patient with low (0) hENT1 expression (A) and high (2+) hENT1 expression (magnification × 400).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bobadilla D, Enriquez E, Alvarez E, Gaytan P, Smith D, Slovak ML. An interphase fluorescence in situ hybridization (FISH) assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. British Journal of Haematology. 2007;136:806–813. - PubMed
    1. Cooper T, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Proceedings of the American Association for Cancer Research. 2003;44:142. - PubMed
    1. Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemotherapy and Pharmacology. 2005;55:361–368. - PubMed
    1. Dabbagh L, Coupland RW, Cass CE, Mackey JR. Immunohistochemical variation of human nucleoside transporters in primary breast cancer. Biochemical and Biophysical Research Communications. 2001;280:951–959. - PubMed
    1. Faderl S, Gandhi V, O’Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Swari M, Keating M, Plunkett W, Kantarjian H. Results of a Phase I–II study of clofarabine in combination with cytarabine (ara-c) in relapsed and refractory leukemias. Blood. 2005;105:940–947. - PubMed

Publication types

MeSH terms